- Home
- USCB vs DBVT Comparison
USCB vs DBVT Comparison
Compare USCB & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USCB
- DBVT
- Stock Information
- Founded
- USCB 2002
- DBVT 2002
- Country
- USCB United States
- DBVT France
- Employees
- USCB N/A
- DBVT N/A
- Industry
- USCB Major Banks
- DBVT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- USCB Finance
- DBVT Health Care
- Exchange
- USCB Nasdaq
- DBVT Nasdaq
- Market Cap
- USCB 316.4M
- DBVT 260.5M
- IPO Year
- USCB 2021
- DBVT N/A
- Fundamental
- Price
- USCB $17.21
- DBVT $9.90
- Analyst Decision
- USCB Strong Buy
- DBVT Buy
- Analyst Count
- USCB 3
- DBVT 4
- Target Price
- USCB $22.00
- DBVT $14.81
- AVG Volume (30 Days)
- USCB 21.0K
- DBVT 36.4K
- Earning Date
- USCB 10-30-2025
- DBVT 11-05-2025
- Dividend Yield
- USCB 2.32%
- DBVT N/A
- EPS Growth
- USCB 67.08
- DBVT N/A
- EPS
- USCB 1.47
- DBVT N/A
- Revenue
- USCB $88,094,000.00
- DBVT $3,800,000.00
- Revenue This Year
- USCB $25.60
- DBVT $1,743.46
- Revenue Next Year
- USCB $5.04
- DBVT $1,045.66
- P/E Ratio
- USCB $11.74
- DBVT N/A
- Revenue Growth
- USCB 32.06
- DBVT N/A
- 52 Week Low
- USCB $13.90
- DBVT $2.21
- 52 Week High
- USCB $21.86
- DBVT $12.78
- Technical
- Relative Strength Index (RSI)
- USCB 49.87
- DBVT 55.65
- Support Level
- USCB $17.16
- DBVT $9.58
- Resistance Level
- USCB $17.50
- DBVT $10.19
- Average True Range (ATR)
- USCB 0.48
- DBVT 0.53
- MACD
- USCB -0.01
- DBVT 0.07
- Stochastic Oscillator
- USCB 28.39
- DBVT 66.39
About USCB USCB Financial Holdings Inc.
USCB Financial Holdings Inc is a community bank. Through its network of branches and its online banking platform, it offers customers a wide range of financial products and services such as Personal and Business Checking, Savings, Credit Cards, and Real Estate Loans.
About DBVT DBV Technologies S.A.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.